Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | ARV-393 |
Synonyms | |
Therapy Description |
ARV-393 is a proteolysis targeting chimera (PROTAC) targeting BCL6, which induces degradation of BCL6 and potentially inhibits tumor growth (Cancer Res (2024) 84 (7_Supplement): ND05) |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ARV-393 | ARV 393|ARV393 | BCL6 Inhibitor 6 | ARV-393 is a proteolysis targeting chimera (PROTAC) targeting BCL6, which induces degradation of BCL6 and potentially inhibits tumor growth (Cancer Res (2024) 84 (7_Supplement): ND05) |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06393738 | Phase I | ARV-393 | A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma. | Not yet recruiting | USA | ESP | 1 |